Novel insights into the molecular origins and treatment of lung cancer.

作者: James D. Webb , M. Celeste Simon

DOI: 10.4161/CC.9.20.13588

关键词:

摘要: Lung cancer remains the foremost cause of deaths worldwide. Despite advances in both detection and treatment, diagnosis is often late prognosis for patients poor. Our understanding molecular basis progression lung incomplete, hampering design development more effective diagnostic tools therapies this devastating disease. However, last twelve months have witnessed publication several studies that represent significant our knowledge cancer, may important steps on road to new therapies. In review we aim summarize these recent developments, give perspectives therapeutic possibilities they offer future.

参考文章(93)
S. Rodenhuis, S. S. Wagenaar, W. J. Mooi, A. J. M. Boot, R. J. C. Slebos, P. C. Van Bodegom, S. G. Evers, J. L. Bos, Incidence and Possible Clinical Significance of K- ras Oncogene Activation in Adenocarcinoma of the Human Lung Cancer Research. ,vol. 48, pp. 5738- 5741 ,(1988)
William N. Rom, Daniel R. Jacobson, Nancy E. Mills, Charles L. Fishman, Neil Dubin, Increased Prevalence of K-ras Oncogene Mutations in Lung Adenocarcinoma Cancer Research. ,vol. 55, pp. 1444- 1447 ,(1995)
Leisa Johnson, Kim Mercer, Doron Greenbaum, Roderick T. Bronson, Denise Crowley, David A. Tuveson, Tyler Jacks, Somatic activation of the K-ras oncogene causes early onset lung cancer in mice Nature. ,vol. 410, pp. 1111- 1116 ,(2001) , 10.1038/35074129
V. Rusch, Ethan Dmitrovsky, C. Cordon-Cardo, S. Hoda, M. Zaman, Jonathan M Kurie, J. Mcintosh, J. Baselga, J. Orazem, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Research. ,vol. 53, pp. 2379- 2385 ,(1993)
M. Ema, S. Taya, N. Yokotani, K. Sogawa, Y. Matsuda, Y. Fujii-Kuriyama, A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development Proceedings of the National Academy of Sciences of the United States of America. ,vol. 94, pp. 4273- 4278 ,(1997) , 10.1073/PNAS.94.9.4273
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Jessica A. Bertout, Shetal A. Patel, M. Celeste Simon, The impact of O2 availability on human cancer Nature Reviews Cancer. ,vol. 8, pp. 967- 975 ,(2008) , 10.1038/NRC2540
William Y Kim, Samanthi Perera, Bing Zhou, Julian Carretero, Jen Jen Yeh, Samuel A Heathcote, Autumn L Jackson, Petros Nikolinakos, Beatriz Ospina, George Naumov, Kathleyn A Brandstetter, Victor J Weigman, Sara Zaghlul, D Neil Hayes, Robert F Padera, John V Heymach, Andrew L Kung, Norman E Sharpless, William G Kaelin, Kwok-Kin Wong, None, HIF2α cooperates with RAS to promote lung tumorigenesis in mice Journal of Clinical Investigation. ,vol. 119, pp. 2160- 2170 ,(2009) , 10.1172/JCI38443
Y Ohsaki, S Tanno, Y Fujita, E Toyoshima, S Fujiuchi, Y Nishigaki, S Ishida, A Nagase, N Miyokawa, S Hirata, K Kikuchi, Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncology Reports. ,vol. 7, pp. 603- 610 ,(2000) , 10.3892/OR.7.3.603
Marta Puyol, Alberto Martín, Pierre Dubus, Francisca Mulero, Pilar Pizcueta, Gulfaraz Khan, Carmen Guerra, David Santamaría, Mariano Barbacid, A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma Cancer Cell. ,vol. 18, pp. 63- 73 ,(2010) , 10.1016/J.CCR.2010.05.025